AC Immune’s (ACIU) Buy Rating Reaffirmed at HC Wainwright

AC Immune (NASDAQ:ACIU)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a report issued on Wednesday, Marketbeat reports. They presently have a $16.00 price objective on the stock. HC Wainwright’s price objective indicates a potential upside of 333.60% from the company’s previous close.

Separately, BTIG Research started coverage on AC Immune in a research report on Friday, May 31st. They set a “buy” rating and a $8.00 target price for the company.

AC Immune Stock Performance

ACIU stock opened at $3.69 on Wednesday. AC Immune has a 52 week low of $2.20 and a 52 week high of $5.14. The company’s 50-day simple moving average is $3.43 and its 200 day simple moving average is $3.39. The company has a market capitalization of $364.94 million, a PE ratio of -5.35 and a beta of 1.24.

AC Immune (NASDAQ:ACIU) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of $0.42 by ($0.67). The firm had revenue of $0.76 million for the quarter, compared to the consensus estimate of $91.60 million. On average, analysts forecast that AC Immune will post -0.89 EPS for the current year.

Institutional Investors Weigh In On AC Immune

A number of large investors have recently bought and sold shares of the company. Redmile Group LLC grew its stake in AC Immune by 0.4% during the first quarter. Redmile Group LLC now owns 2,007,031 shares of the company’s stock worth $5,941,000 after buying an additional 7,031 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of AC Immune by 315.6% in the first quarter. BNP Paribas Financial Markets now owns 11,092 shares of the company’s stock worth $33,000 after acquiring an additional 8,423 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of AC Immune by 96.5% in the first quarter. China Universal Asset Management Co. Ltd. now owns 19,008 shares of the company’s stock worth $56,000 after acquiring an additional 9,334 shares during the last quarter. Silverberg Bernstein Capital Management LLC bought a new position in shares of AC Immune in the second quarter worth about $40,000. Finally, Lazard Asset Management LLC bought a new position in shares of AC Immune in the first quarter worth about $30,000. 51.36% of the stock is currently owned by institutional investors and hedge funds.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.